Akeso
Akeso, Inc., a leading biopharmaceutical company headquartered in China (CN), is renowned for its innovative approach in the fields of oncology and autoimmune diseases. Founded in 2007, Akeso has rapidly established itself as a key player in the biopharma industry, with a strong focus on the research, development, and commercialisation of monoclonal antibodies and bispecific antibodies. With major operational regions across Asia and expanding into global markets, Akeso's core products include its proprietary therapies that target various cancers and immune disorders. The company is distinguished by its commitment to advancing biologics, leveraging cutting-edge technology to enhance treatment efficacy. Notably, Akeso has achieved significant milestones, including successful clinical trials and partnerships that bolster its market position, making it a formidable contender in the competitive biopharmaceutical landscape.
DitchCarbon Score
How does Akeso's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Akeso's score of 19 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Akeso's reported carbon emissions
In 2023, Akeso reported total carbon emissions of approximately 28,229,430 kg CO2e, comprising about 1,397,580 kg CO2e from Scope 1 and about 26,831,850 kg CO2e from Scope 2 emissions. This represents a significant increase from 2022, where total emissions were about 23,740,020 kg CO2e, with Scope 1 emissions at approximately 82,000 kg CO2e and Scope 2 emissions at about 23,658,020 kg CO2e. In 2021, Akeso's emissions were approximately 4,530,880 kg CO2e, with Scope 1 emissions at about 35,230 kg CO2e and Scope 2 emissions at about 4,495,650 kg CO2e. Despite the increase in emissions over the past two years, Akeso has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The company has not made commitments to the Science Based Targets initiative (SBTi) or other climate pledges, indicating a potential area for future focus in their sustainability strategy. Overall, Akeso's emissions data highlights the need for enhanced climate commitments and reduction strategies to align with global sustainability goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 35,230 | 00,000 | 0,000,000 |
| Scope 2 | 4,495,650 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Akeso is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
